LUCD logo

LUCD
Lucid Diagnostics Inc

1,872
Mkt Cap
$221.18M
Volume
704,974.00
52W High
$1.70
52W Low
$0.9495
PE Ratio
-1.52
LUCD Fundamentals
Price
$1.30
Prev Close
$1.25
Open
$1.25
50D MA
$1.30
Beta
0.68
Avg. Volume
630,508.16
EPS (Annual)
-$0.6922
P/B
-3.78
Rev/Employee
$57,390.24
$156.51
Loading...
Loading...
News
all
press releases
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) have received an average recommendation of "Moderate Buy" from the five research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a b...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Lucid Diagnostics (NASDAQ:LUCD) Price Target Raised to $9.00
Ascendiant Capital Markets boosted their price objective on shares of Lucid Diagnostics from $8.25 to $9.00 and gave the stock a "buy" rating in a research note on Thursday...
MarketBeat·11d ago
News Placeholder
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual...
PR Newswire·11d ago
News Placeholder
Lucid Diagnostics Inc. $LUCD Shares Purchased by Aberdeen Group plc
Aberdeen Group plc boosted its stake in Lucid Diagnostics Inc. (NASDAQ:LUCD - Free Report) by 38.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·12d ago
News Placeholder
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio PR Newswire NEW YORK, April 2, 2026 Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical...
PR Newswire·18d ago
News Placeholder
Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Update
Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 5,797,071 shares, a decline of 13.8% from the February 26th total of 6,727,046 shares. Based on an average daily trading volume...
MarketBeat·20d ago
News Placeholder
Lucid Diagnostics (NASDAQ:LUCD) Earns Buy Rating from BTIG Research
BTIG Research reaffirmed a "buy" rating and set a $2.50 target price on shares of Lucid Diagnostics in a report on Monday...
MarketBeat·21d ago
News Placeholder
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results PR...
PR Newswire·21d ago
News Placeholder
Lucid Diagnostics (NASDAQ:LUCD) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised shares of Lucid Diagnostics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·24d ago
News Placeholder
Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.03 EPS
Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts...
MarketBeat·24d ago
<
1
2
...
>

Latest LUCD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.